The tweet was deleted by the author.
But we saved everything 🙂.
Camp4 Therapeutics Corp is sharpening its R and D strategy amid tighter capital conditions, according to remarks by CFO Kelly Gold.
The company is placing greater emphasis on program prioritization and seeking new partnerships to advance its pipeline, with a particular focus on therapies for haploinsufficient diseases. Camp4 Therapeutics Corp aims to optimize resource allocation while continuing to pursue innovative drug development. Details were shared during #FierceBiotechWeek.
Last month, Camp4 Therapeutics Corp hosted an employee ski outing to support team engagement and recognize staff contributions. Earlier, the company released a preprint on its new regRNA catalog powered by Capture-seq technology for gene expression applications. These initiatives followed ongoing efforts to advance drug development and resource allocation.